VPT:CC - Ventripoint Welcomes Bart Hendriks as New Strategic Partnerships Executive to Accelerate European and Global Sales
(TheNewswire)
Toronto, Ontario – TheNewswire - February 13, 2024 – Ventripoint Diagnostics Ltd. ("Ventripoint" orthe "Company"),(TSXV:VPT ) ( OTC:VPTDF) is delighted to welcome Bart Hendriks as thecompany's new Strategic Partnerships Executive, to accelerate adoptionof Ventripoint’s AI-powered, heart-scanning technology by hospitalsand clinics in Europe and around the world.
A seasoned professional in the MedTech artificial intelligence field,Bart brings a wealth of experience from his tenure in variousleadership capacities, including CEO and Founder of innovativeventures in medical technology, diagnostics, and AI-driven clinicalapplications.
Based in The Netherlands, Bart will focus on expanding European andglobal sales of Ventripoint’s technology, which analyses ultrasoundscans and provides MRI-quality measurements of the heart, at thefraction of the cost and time and trauma of MRIs.
“Bart has excelled in global sales and marketing management,strategic partner development, change management, and has shownadeptness in mergers and acquisitions, deal structuring, negotiationsand team leadership,” said Ventripoint’s Interim CEO HughMacNaught. “Our focus is now commercialization of Ventripoint’stechnology. Bart’s track record includes successfully closingmultiple funding rounds, securing strategic contracts, and drivingsubstantial revenue growth across different organizations. “
Hendriks’ role begins immediately. His full bio is .
Added Hendriks: “Ventripoint's technology is unique, offering arevolutionary mix of precision, efficiency, and user-friendliness incardiac diagnostics using artificial intelligence. This cutting-edgetool is set to alter the paradigm of heart health management, makingcardiac scans more accessible and effective for patients across theglobe, and offers a portable, inexpensive alternative to MRIs thattakes only minutes.”
For further information, pleasecontact:
Jonathan Robinson CFA
(416) 669-1001
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
About Ventripoint DiagnosticsLtd.
Ventripoint has become an industry leader in the application of AI(Artificial Intelligence) to echocardiography. Ventripoint's VMSproducts are powered by its proprietary KBR technology, which is theresult of a decade of development and provides accurate volumetriccardiac measurements equivalent to MRI. This affordable, gold-standardalternative allows cardiologists greater confidence in the managementof their patients. Providing better care to patients serves as aspringboard and basic standard for all Ventripoint's products thatguide our future developments. In addition, VMS+ is versatile and canbe used with all ultrasound systems from any vendor supported byregulatory market approvals in the U.S., Europe and Canada.
Forward Looking Statements
This news release contains forward-looking statements andforward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and information address future eventsand conditions, by their very nature they involve inherent risks anduncertainties. Actual results could differ materially from thosecurrently anticipated due to several factors and risks. Factors whichcould materially affect such forward-looking information are describedin the risk factors in the Company's most recent annual management'sdiscussion and analysis that is available on the Company's profile onSEDAR at www.sedar.com. Readers are cautioned that theforegoing list of factors is not exhaustive. The forward-lookingstatements included in this news release are expressly qualified bythis cautionary statement. The forward-looking statements andinformation contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether becauseof new information, future events or otherwise, unless so required byapplicable securities laws.
Copyright (c) 2024 TheNewswire - All rights reserved.